Picture of Avrobio logo

AVRO — Avrobio Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Momentum

Relative Strength (%)
1m-46.93%
3m-62.93%
6m-74.03%
1yr-88.82%
Volume Change (%)
10d/3m+44.56%
Price vs... (%)
52w High-90.48%
50d MA-44.7%
200d MA-71.04%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-61.42%
Return on Equity-59.3%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Avrobio EPS forecast chart

Profile Summary

AVROBIO, Inc. is a clinical-stage gene therapy company. The Company is focused on developing curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Its gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with a lentiviral vector to insert a functional copy of the gene that is defective in the target disease. The Company is focusing on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies. Its pipeline is comprised of six lentiviral-based gene therapy programs, which includes AVR-RD-01 for the treatment of Fabry disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-06 for the treatment of Gaucher disease type 3; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
November 17th, 2015
Public Since
June 21st, 2018
No. of Shareholders
8
No. of Employees
121
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
43,632,000

AVRO Share Price Performance

Latest News for AVRO

Upcoming Events for AVRO

Q4 2021 AVROBIO Inc Earnings Release

Q1 2022 AVROBIO Inc Earnings Release

AVROBIO Inc Annual Shareholders Meeting

Similar to AVRO

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email